maintenance therapy

In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:

• Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
• Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
• When to consider first-line treatment with immune checkpoint inhibitor monotherapy
• Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy

Presenters:

Georgios Gakis, MD  
Professor of Urology, Staff Urologist
University Hospital of Würzburg  
Würzburg, Germany

Mario Wolfgang Kramer, MD, PhD  
Consultant Urologist
Vice Director, Urology
University Hospital Schlewig-Holstein Campus Lübeck
Lübeck, Germany

Content based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc.

Link to full program, including associated downloadable slidesets and on-demand webcast:
https://bit.ly/3kJC5SL

In this episode, Félix Guerrero Ramos, MD, PhD, FEBU, and Óscar Rodríguez-Faba, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer. 

Presenters:

Félix Guerrero Ramos, MD, PhD, FEBU 
Teaching Collaborator
Department of Surgery
Medicine School
Universidad Complutense de Madrid
Attending Urologist
Department of Urology
UroOncology Unit
Madrid, Spain 

Óscar Rodríguez-Faba, MD 
Urologist
Uro-Oncology
Fundació Puigvert
Barcelona, Catalonia, Spain

Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.

Link to full program, including associated downloadable slidesets and on-demand Webcast:
http://bit.ly/3kJC5SL

In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:

• Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settings
• Utility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapy
• Results from the JAVELIN trial on avelumab maintenance after chemotherapy
• When to consider first-line treatment with immune checkpoint inhibitor–based therapy vs chemotherapy

Presenters:

Thomas Powles, MBBS, MRCP, MD
Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom

Michiel van der Heijden, MD, PhD
Medical Oncologist and Research Group Leader
Department of Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist 
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, the Netherlands

Content based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.

Link to full program, including associated downloadable slidesets and on-demand Webcast:
https://bit.ly/3kJC5SL

In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer. 

Presenters:

Alain Ravaud, MD, PhD 
Professor of Medical Oncology
Head of Department of Medical Oncology
Bordeaux University Hospital
Bordeaux, France

Marine Gross-Goupil, MD, PhD 
Medical Oncologist
Saint-André Hospital
Bordeaux University Hospital
Bordeaux, France

Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.

Link to full program:
https://bit.ly/3kJC5SL

In this episode, Isabelle Ray Coquard, MD, PhD and Bradley J. Monk, MD, FACS, FACOG, discuss current first-line maintenance therapy options for patients with advanced ovarian cancer. 

Presenters:

Prof Isabelle Ray Coquard
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Bradley J. Monk MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine--Phoenix
Creighton University School of Medicine at St Joseph's Hospital
Phoenix, Arizona

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program:
https://bit.ly/2Scnp2N